Company ChitogenX Inc.

Equities

CHGX

CA1699161032

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 09:34:23 2024-04-19 am EDT			5-day change	1st Jan Change
0.065 ^CAD	0.00%		+62.50%	0.00%

Feb. 28	Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors	CI
Feb. 28	Chitogenx Inc. Announces CEO Changes	CI

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Companyâs proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.

Managers	Title	Age	Since
Pierre Laurin CEO	Chief Executive Officer	63	19-06-18
Luc Mainville DFI	Director of Finance/CFO	60	18-09-17
Mukesh Ahuja CTO	Chief Tech/Sci/R&D Officer	-	20-10-31
Michael Buschmann CTO	Chief Tech/Sci/R&D Officer	62	15-02-04
H. Norton BRD	Director/Board Member	63	16-07-25
Steven Saviuk BRD	Director/Board Member	65	15-02-04
Frédéric Dumais IRC	Investor Relations Contact	-	19-05-31
Guy-Paul Allard LAW	General Counsel	56	16-06-22

Members of the board	Title	Age	Since
Pierre Laurin CEO	Chief Executive Officer	63	19-06-18
Steven Saviuk BRD	Director/Board Member	65	15-02-04
Timothy Cunningham BRD	Director/Board Member	62	21-06-13
H. Norton BRD	Director/Board Member	63	16-07-25
Patrick O'Donnell BRD	Director/Board Member	59	21-02-23
Michael Buschmann CTO	Chief Tech/Sci/R&D Officer	62	15-02-04
Howard Walthall BRD	Director/Board Member	52	21-06-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	83,129,520	61,308,018 ( 73.75 %)	0	73.75 %

Name	Equities	%	Valuation
MANITEX CAPITAL INC. 10.34 %	5,275,392	10.34 %	226 842 $
Luc Mainville 7.086 %	3,616,678	7.086 %	155 517 $
Philippe Deschamps 5.107 %	2,606,718	5.107 %	112 089 $
Pierre Laurin 5.105 %	2,605,432	5.105 %	112 034 $
Caroline D. Hoemann 4.095 %	2,090,222	4.095 %	89 880 $
Guy-Paul Allard 2.418 %	1,234,250	2.418 %	53 073 $
H. Norton 2.344 %	1,196,443	2.344 %	51 447 $
Jonathan Sackier 1.234 %	630,000	1.234 %	27 090 $
Timothy Cunningham 0.000000 %	0	0.000000 %	- $
Patrick O'Donnell 0.000000 %	0	0.000000 %	- $

ChitogenX, Inc.

16667 Hymus Boulevard

H9H 4R9, Kirkland

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHITOGENX INC.	0.00%	3.94M
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+43.29%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research